Gordon Freedman is the founder and president of the National Laboratory for Education Transformation (NLET, www.NLET.org), a California-based nonprofit that now anchors several initiatives driving what he calls the “mitochondrial revolution” in medicine and health. Through NLET, he founded MitoWorld.org as a neutral, science-forward public gateway to mitochondrial biology, curating expert content, interviews, and explainers that connect cutting-edge research to clinicians, patients, investors, and policy makers.Building on this foundation, Freedman launched MITOS.org as an emerging global collaboration platform focused on translating mitochondrial science into diagnostics, therapeutics, and prevention strategies. MITOS convenes researchers, clinicians, and technology partners to identify high-value opportunities in areas such as metabolic disease, neurodegeneration, immune dysfunction, aging, and women’s health, while emphasizing rigorous validation and cross-disciplinary collaboration.Freedman’s work sits at the intersection of biomedicine, data, and systems transformation. Drawing on his background in large-scale education and workforce innovation, he is building new narratives, tools, and coalitions to move mitochondria from a niche specialty to a central organizing framework for understanding human biology and environmental stress. Through MitoWorld.org and MITOS.org, he is assembling scientific advisory networks, mapping the global mitochondrial research landscape, and designing communication and funding strategies that can support the next generation of mitochondrial diagnostics and interventions.At SynBioBeta 2026, Freedman’s session on mitochondrial advances will highlight how synthetic biology, precision measurement, and high-throughput screening can unlock mitochondrial mechanisms as platforms for drug discovery, cell and gene therapies, and systems-level models of human health. His goal is to help bridge pioneering mitochondrial science with the entrepreneurial, engineering, and investment communities needed to scale mitochondrial innovation for global impact.